← Back to all trials
Active Not Recruiting
NCT06857955
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Conditions: Hypertension
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 399
Sponsor: Novartis Pharmaceuticals
Location: SEC Clinical Research LLC Andalusia Alabama
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Eligibility Criteria
Inclusion Criteria:
1. Signed informed consent.
2. Males or females aged 18 to 75 years.
3. Diagnosis of hypertension.
4. Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo washout for 4 weeks.
5. Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and \
Source: ClinicalTrials.gov (NCT06857955). StuddyBuddy aggregates publicly available trial information.
